CRISPR editing to inactivate ANGPTL3 gene
Gene editing has been used in preclinical safety and efficacy testing to inactivate the ANGPTL3 gene, with the aim of developing novel therapies for homozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Read More > CRISPR editing to inactivate ANGPTL3 gene